Verastem Will Present RAMP 201 Trial Data in October
The clinical trial results for a combination therapy in ovarian cancer patients will be revealed at an upcoming global meeting.
Updated on Sept. 24, 2026 in Cancer
Live Poll
Do you trust that clinical trial data reliably proves the benefits of new cancer medications?
Verastem Oncology is scheduled to present new clinical data from its RAMP 201 Phase 2 trial at the International Gynecologic Cancer Society (IGCS) 2026 Annual Global Meeting in Montreal. The presentations, set for October 2, 2026, will detail findings on an investigational drug combination for recurrent low-grade serous ovarian cancer.
Why it matters
This presentation provides critical insight into the efficacy of a dual-drug therapy designed to block signaling pathways that drive tumor growth and drug resistance. The data will help clarify the performance of this combination compared to monotherapy in patients with recurrent low-grade serous ovarian cancer.
The RAMP 201 trial evaluates the combination of 3.2 mg of avutometinib and 200 mg of defactinib. This regimen addresses the approximately 80,000 women living with low-grade serous ovarian cancer globally.
The players
Verastem Oncology
A biopharmaceutical company focused on developing small molecule drugs for cancer treatment.
Susana N. Banerjee
A researcher who will present data regarding molecular profiling and tumor biomarkers.
Shogo Shigeta
A researcher presenting results from the RAMP 201J study in Japanese patients.
Rachel Grisham
A researcher presenting an analysis of an external control arm for the study.
The details
The trial utilizes a multicenter, open-label design to assess whether combining the two medications provides a more comprehensive blockade of tumor-promoting signals than using either drug alone. Researchers will report on molecular profiling, tumor biomarker analysis, and an external control arm study to support the development path for these therapies.
Timeline
The IGCS Annual Global Meeting takes place from October 1 to October 3, 2026.
Presentations for RAMP 201 and RAMP 201J occur on October 2, 2026, at 10:30 a.m. ET.
The presentation for the external control arm analysis is scheduled for October 2, 2026, at 2:25 p.m. ET.
The Big Picture
Following the FDA approval of AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated recurrent LGSOC, this research expands the understanding of these treatments beyond initial regulatory approval. The findings mark a continued effort to confirm clinical benefits in larger, standardized international cohorts.
These clinical findings may eventually expand the range of available therapeutic options for patients battling recurrent low-grade serous ovarian cancer. Patients should consult with their oncologists to determine how evolving data on combination therapies might influence future treatment plans.
The takeaway
Patients and providers should monitor these findings to understand the potential role of dual-therapy signaling blockade in managing gynecologic malignancies. The ongoing Phase 3 trial will remain a critical factor in determining the long-term standard of care for this patient population.
Further reading
For additional context on research in this field, visit the Cancer section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust that clinical trial data reliably proves the benefits of new cancer medications?
